A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

RegeneRx Biopharmaceuticals, Inc. · ClinicalTrials.gov registration

Terminated, with the registry recording lack of patient availability and expiry of the study drug. No results were posted and none are indexed — the epidermolysis bullosa question was never answered either way.

Population

Patients with epidermolysis bullosa; 30 planned

Intervention

Topical thymosin β4

Comparator

Placebo

Limitations

Registration record only; a terminated trial is an absence of data, not a negative result, and review articles describing Tβ4 as helping epidermolysis bullosa lesions are not drawing on a completed controlled trial.